EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dual‐Targeting of the HER2 Cancer Receptor with an Antibody‐Directed Enzyme and a Nanobody‐Guided MMAE Prodrug Scaffold

Jakob Melgaard Smidt, Anders Märcher, Mads Koch Skaanning, Kassem El-Chami, Laura Teodori, Marjan Omer, Jørgen Kjems, Kurt V Gothelf

ChemBioChem · 2024

DOI: 10.1002/cbic.202400437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2024. Verfasst von Jakob Melgaard Smidt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Nanoscience Center (iNANO) and Department of Chemistry, Aarhus University, Gustav Wieds Vej 14, 8000, Aarhus, Denmark. Hauptthemen laut MEDLINE: Prodrugs, Erb-b2 Receptor Tyrosine Kinases, Oligopeptides, Single-Domain Antibodies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Foundation (CEMBID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody‐enzyme conjugates have shown potential as tissue‐specific prodrug activators by antibody‐directed enzyme prodrug therapy (ADEPT), but the approach met challenges clinically due to systemic drug release. Here, we report a novel dual‐targeting ADEPT system (DuADEPT) which is based on active cancer receptor targeting of both a trastuzumab‐sialidase conjugate (Tz‐Sia) and a highly potent sialidase‐activated monomethyl auristatin E (MMAE) prodrug scaffold. The scaffold is based on a four‐way junction of the artificial nucleic acid analog acyclic ( L )‐threoninol nucleic acid (( L )‐aTNA) which at the ends of its four arms carries one nanobody targeting HER2 and three copies of the prodrug. Dual‐targeting of the constructs to two proximal epitopes of HER2 was shown by flow cytometry, and a dual‐targeted enzymatic drug release assay revealed cytotoxicity upon prodrug activation specifically for HER2‐positive cancer cells. The specific delivery and activation of prodrugs in this way could potentially be used to decrease systemic side effects and increase drug efficacy, and utilization of Tz‐Sia provides an opportunity to combine the local chemotherapeutic effect of the DuADEPT with an anticancer immune response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsErb-b2 Receptor Tyrosine KinasesOligopeptidesSingle-Domain AntibodiesHumansTrastuzumabNeuraminidaseCell Line, TumorAntineoplastic AgentsImmunoconjugates

Stichwörter der Autor:innen

ADEPTBioconjugationNanobodyProdrugaTNA

Substanzen

ProdrugsErb-b2 Receptor Tyrosine KinasesOligopeptidesSingle-Domain AntibodiesTrastuzumabNeuraminidaseAntineoplastic AgentsImmunoconjugatesmonomethyl auristatin EERBB2 protein, human

Autor:innen und Institutionen

  • Interdisciplinary Nanoscience Center (iNANO) and Department of Chemistry, Aarhus University, Gustav Wieds Vej 14, 8000, Aarhus, Denmark.
  • Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 14, 8000, Aarhus, Denmark.

Förderung

  • Novo Nordisk Foundation (CEMBID)

Zitieren

APA

Smidt, J. M., Märcher, A., Skaanning, M. K., El-Chami, K., Teodori, L., Omer, M., Kjems, J., & Gothelf, K. V. (2024). Dual‐Targeting of the HER2 Cancer Receptor with an Antibody‐Directed Enzyme and a Nanobody‐Guided MMAE Prodrug Scaffold. ChemBioChem. https://doi.org/10.1002/cbic.202400437

Vancouver

Smidt JM, Märcher A, Skaanning MK, El-Chami K, Teodori L, Omer M, et al. Dual‐Targeting of the HER2 Cancer Receptor with an Antibody‐Directed Enzyme and a Nanobody‐Guided MMAE Prodrug Scaffold. ChemBioChem. 2024. doi:10.1002/cbic.202400437

BibTeX
@article{Smidt2024,
  author = {Smidt, Jakob Melgaard and Märcher, Anders and Skaanning, Mads Koch and El-Chami, Kassem and Teodori, Laura and Omer, Marjan and Kjems, Jørgen and Gothelf, Kurt V},
  title = {Dual‐Targeting of the HER2 Cancer Receptor with an Antibody‐Directed Enzyme and a Nanobody‐Guided MMAE Prodrug Scaffold},
  journal = {ChemBioChem},
  year = {2024},
  doi = {10.1002/cbic.202400437}
}
Kostenlos starten →